PCSK9 and type 2 diabetes mellitus: The MR study found PCSK9 variants to have a similar effect as HMGCR variants on the risk of cardiovascular events (OR 0.81, 0.74–0.89 vs OR 0.81, 0.72–0.90) and the risk of type 2 diabetes (OR 1.11, 1.04–1.19 vs 1.13, 1.06–1.20) for each 10 mg per dl decrease in LDL cholesterol level.